Nathalie Fiaschi

机构：Regeneron (United States) · ORCID：0000-0003-2836-2751

发表论文 39 篇 · 总被引 1246 次 · h-index 11

代表论文

• Intratumoral dendritic cell–CD4+ T helper cell niches enable CD8+ T cell differentiation following PD-1 blockade in hepatocellular carcinoma (2023 · Nature Medicine · 被引 429)
• CD22-targeted CD28 bispecific antibody enhances antitumor efficacy of odronextamab in refractory diffuse large B cell lymphoma models (2022 · Science Translational Medicine · 被引 54)
• Phase I Study of Fianlimab, a Human Lymphocyte Activation Gene-3 (LAG-3) Monoclonal Antibody, in Combination With Cemiplimab in Advanced Melanoma (2024 · Journal of Clinical Oncology · 被引 41)
• Molecular assessment of intratumoral immune cell subsets and potential mechanisms of resistance to odronextamab, a CD20×CD3 bispecific antibody, in patients with relapsed/refractory B-cell non-Hodgkin lymphoma (2024 · Journal for ImmunoTherapy of Cancer · 被引 28)
• Humoral IgG1 responses to tumor antigens underpin clinical outcomes in immune checkpoint blockade (2026 · Nature Medicine · 被引 13)
• Complete responses to odronextamab in two patients with diffuse large B‐cell lymphoma refractory to chimeric antigen receptor T‐cell therapy (2022 · British Journal of Haematology · 被引 7)